Anti-diabetic medicines that activate the protein PPAR had a shiny start
Anti-diabetic medicines that activate the protein PPAR had a shiny start but soon shed appeal because of undesirable unwanted effects. very similar capability to revert CDK5-mediated phosphorylation. In solid support of the hypotheses, Choi em et al. /em 1 present that, in individual patients getting rosiglitazone, the degrees of phosphorylated PPAR in unwanted fat tissue … [Read more…]